RECOMBINANT GROWTH-FACTORS TRANSFUSION SCIENCE GOODNOUGH, L. T., Anderson, K. C. 1995; 16 (1): 45-62

Abstract

Recombinant human growth factors are expected to have a significant impact on the use of allogeneic blood components. For example, subsequent to the approval of recombinant human erythropoietin, blood transfusions in renal dialysis patients declined substantially. Likewise, myeloid growth factors have reduced infections and hospital stay by promoting hematologic recovery after high dose ablative chemotherapy. The high costs of these agents mandate that their use be limited to settings where they are clinically indicated. The use of growth factors may be monitored at medical centers by hospital transfusion committees. This chapter reviews the emerging clinical guidelines for the use of hematopoietic growth factors.

View details for Web of Science ID A1995QM02800006

View details for PubMedID 10155704